Synthesis, Crystal Structure, Structure−Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor
journal contributionposted on 10.08.2006 by Syaulan Yang, Shu-Jen Chen, Min-Feng Hsu, Jen-Dar Wu, Chien-Te K. Tseng, Yu-Fan Liu, Hua-Chien Chen, Chun-Wei Kuo, Chi-Shen Wu, Li-Wen Chang, Wen-Chang Chen, Shao-Ying Liao, Teng-Yuan Chang, Hsin-Hui Hung, Hui-Lin Shr, Cheng-Yuan Liu, Yu-An Huang, Ling-Yin Chang, Jen-Chi Hsu, Clarence J. Peters, Andrew H.-J. Wang, Ming-Chu Hsu
Any type of content formally published in an academic journal, usually following a peer-review process.
A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG-0205221, Ki = 53 nM) has been developed. TG-0205221 showed remarkable activity against SARS CoV and human coronavirus (HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 μM) for SARS CoV and 5.2 log (at 1.25 μM) for HCoV 229E. The crystal structure of TG-0205221 (resolution = 1.93 Å) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG-0205221 and a natural peptide substrate were also discussed. This information may be applied toward the design of other 3CL protease inhibitors.